uniQure N.V. (GB:0EE0)
LSE:0EE0

uniQure (0EE0) Share Price & Analysis

0 Followers

0EE0 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$13.28 - $27.78
Previous Close$19.21
Volume48.00
Average Volume (3M)505.00
Market Cap
$954.06M
Enterprise Value$942.20M
Total Cash (Recent Filing)$153.85M
Total Debt (Recent Filing)$142.00M
Price to Earnings (P/E)N/A
Beta0.63
Aug 02, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,580,000
10 Day Avg. Volume215
30 Day Avg. Volume505
Standard Deviation0.23
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.81
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.00
Enterprise Value/Gross Profit-281.84
Enterprise Value/Ebitda-6.74
Forecast
Price Target Upside185.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9


Financials

Annual

0EE0 FAQ

What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest share price was $13.28 and its highest was $27.78 in the past 12 months.
    What is uniQure N.V.’s market cap?
    Currently, no data Available
    When is uniQure N.V.’s upcoming earnings report date?
    uniQure N.V.’s upcoming earnings report date is Aug 02, 2023 which is in 58 days.
      How were uniQure N.V.’s earnings last quarter?
      uniQure N.V. released its earnings results on May 09, 2023. The company reported -$1.63 earnings per share for the quarter, missing the consensus estimate of -$0.947 by -$0.683.
        Is uniQure N.V. overvalued?
        According to Wall Street analysts uniQure N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does uniQure N.V. pay dividends?
          uniQure N.V. does not currently pay dividends.
          What is uniQure N.V.’s EPS estimate?
          uniQure N.V.’s EPS estimate is $1.15.
            How many shares outstanding does uniQure N.V. have?
            Currently, no data Available
            What happened to uniQure N.V.’s price movement after its last earnings report?
            uniQure N.V. reported an EPS of -$1.63 in its last earnings report, missing expectations of -$0.947. Following the earnings report the stock price went up 0.713%.
              Which hedge fund is a major shareholder of uniQure N.V.?
              Among the largest hedge funds holding uniQure N.V.’s share is Woodline Partners LP. It holds uniQure N.V.’s shares valued at 3M.

                ---

                uniQure Stock Smart Score

                The uniQure Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                uniQure N.V.

                uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                uniQure
                Abeona Therapeutics
                Adverum Biotechnologies
                Bellicum Pharmaceuticals
                Crispr Therapeutics AG

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis